With the DSCSA deadline less than a year away and continued efforts to protect patients from counterfeits, 2017 is beginning with two conferences to educate industry on best practices for pharmaceutical distribution and anti-counterfeiting techniques. The subjects are timely, as estimates of the percentage of counterfeit branded drugs in developing nations remain high: between 10 and 30% according to the World Health Organization (WHO).
2017 Distribution Management Conference and Expo
In the U.S., the Healthcare Distribution Alliance (HDA, formerly HDMA)
is holding its 2017 Distribution Management Conference and Expo on March 5 to 8 in Palm Desert, CA. HDA’s largest supply chain educational event is co-hosted by the International Federation of Pharmaceutical Wholesalers (IFPW) and the Canadian Association for Pharmacy Distribution Management (CAPDM).
Manufacturers, distributors, consultants and third parties in the pharmaceutical space will be in attendance. The 2017 agenda will offer content in the following areas:
-
Data exchange in the pharmaceutical supply chain
-
Combating prescription drug abuse
-
Product traceability/DSCSA implementation
-
Pharmaceutical supply chain security
-
Specialty pharmaceutical distribution trends
-
Contract administration and chargebacks (new for 2017)
-
Developing the next generation of supply chain professionals
3rd Anti-Counterfeiting Pharma Conference 2017
Research and Markets has announced the 3rd Anti-Counterfeiting Pharma Conference 2017 taking place in London, March 7 to 8. With the size of the global counterfeit drug market in the billions, and the dangers of these drugs to patients, the industry must continue to evolve and fight back to secure the supply chain.
At the conference, industry experts, including speakers from Pfizer and GSK, will share insights on the following:
-
Anti-counterfeiting - the current picture
-
Contemporary anti-counterfeiting and brand protection technologies
-
Review of E.U. and U.S. anti-counterfeiting legislation
-
Measures to secure the supply chain
-
Optimizing the outreach of anti-counterfeiting resource deployment
-
Understanding global regulatory laws
-
Best practices for fighting online counterfeiting
-
Sensitizing the environment about counterfeit pharma products
-
Developing the right serialization strategy
-
Improved tools for patient safety
